Ruba Noorali

Shearman & Sterling (London)
Lawyer (Associate)

Ruba Noorali is an associate at Shearman & Sterling in London in the Antitrust practice. Her practice focuses on EU competition law. Ruba also has experience advising on a range of private M&A transactions.

Distinctions

Linked authors

Shearman & Sterling (London)
Reed Smith (Brussels)
Shearman & Sterling (London)
Shearman & Sterling (Brussels)
Shearman & Sterling (Brussels)
Shearman & Sterling (Frankfurt)

Articles

1452 Bulletin

Alfred Kossmann, James Webber, Ruba Noorali, Elvira Aliende Rodriguez The EU Commission introduces a Temporary Framework which enables governments to offer extensive State-backed loans to the aviation industry affected by the COVID-19

50

Although the EU’s introduction of a Temporary Framework has enabled governments to offer extensive State-backed loans, the airline industry needs more than just credit—it will need equity. However, State aid to the aviation industry is strictly regulated by the European Commission (the (...)

James Webber, Ruba Noorali, Sara Ashall, Matthew Readings, Elvira Aliende Rodriguez The EU Commission announces a major relaxation of the State aid rules via a new Temporary Framework during the COVID-19 outbreak

149

How will European Competition Enforcers Respond? The COVID-19 pandemic presents an unprecedented challenge to the economy and competition enforcement is no exception. Authorities at EU and national level may need to consider novel solutions to respond to rapidly evolving problems and to (...)

Elvira Aliende Rodriguez, Ruba Noorali, Matthew Readings The EU General Court reaffirms the Commission’s duty to provide sufficient reasons when explaining fine calculations in cartel cases (HSBC)

441

On 24 September 2019, the EU General Court (GC) handed down its judgment in HSBC v. Commission. Consistent with recent precedent, the GC reaffirmed the European Commission (“Commission”)’s duty to provide sufficient reasons when explaining fine calculations in cartel cases and annulled the fine (...)

Geert Goeteyn, James Webber, Matthew Readings, Ruba Noorali The EU Commission considers potential harm to innovation as part of its merger assessments, particularly in R&D driven sectors such as pharmaceuticals and technology (Bayer / Monsanto)

812

The European Commission has routinely considered potential harm to innovation as part of its merger assessments, particularly in R&D driven sectors such as pharmaceuticals and technology. In recent years, however, the Commission’s traditional innovation concerns have developed into broader, (...)

Send a message